← Back to Search

Anti-tumor antibiotic

Pembrolizumab for Ovarian Cancer

Phase 2
Waitlist Available
Led By Ursula Matulonis, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This study is evaluating whether a combination of chemotherapy and immunotherapy might be a better treatment for ovarian cancer.

Eligible Conditions
  • Ovarian Cancer
  • Peritoneal Neoplasm

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical Benefit Rate [CBR]
Secondary outcome measures
Duration of Response [DOR]
Overall Response Rate [ORR]
Overall Survival
+2 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pembrolizumab in Combination With PLDExperimental Treatment2 Interventions
A safety lead in with 6 patients will be studied prior the start of the treatment. If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced. If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD) Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved
Doxorubicin
FDA approved

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,078 Previous Clinical Trials
340,846 Total Patients Enrolled
39 Trials studying Ovarian Cancer
4,504 Patients Enrolled for Ovarian Cancer
Merck Sharp & Dohme LLCIndustry Sponsor
3,878 Previous Clinical Trials
5,053,171 Total Patients Enrolled
41 Trials studying Ovarian Cancer
6,574 Patients Enrolled for Ovarian Cancer
Ursula Matulonis, MDPrincipal InvestigatorDana-Farber Cancer Institute
5 Previous Clinical Trials
322 Total Patients Enrolled
3 Trials studying Ovarian Cancer
76 Patients Enrolled for Ovarian Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Ursula A. Matulonis, MD 2016. "Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02865811.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top